Format

Send to

Choose Destination
Anticancer Res. 2015 Mar;35(3):1757-62.

Proton beam therapy combined with concurrent chemotherapy for esophageal cancer.

Author information

1
Department of Radiation Oncology, University of Tsukuba, Faculty of Medicine, Ibaraki, Japan hishikawa@pmrc.tsukuba.ac.jp.
2
Department of Radiation Oncology, University of Tsukuba, Faculty of Medicine, Ibaraki, Japan.
3
Department of Gastroenterology, University of Tsukuba, Faculty of Medicine, Ibaraki, Japan.
4
Gastroenterological and Hepatobiliary Surgery, University of Tsukuba, Faculty of Medicine, Ibaraki, Japan.

Abstract

BACKGROUND/AIM:

The aim of the present study was to evaluate the outcomes of proton beam therapy (PBT) concurrently combined with chemotherapy consisting of cisplatin and 5-fluorouracil for esophageal cancer.

PATIENTS AND METHODS:

Forty consecutive patients (stage I in 16 patients, II in 9 and III in 15) treated between 2008 and 2012 were evaluated. A total dose of 60 Gray equivalents (GyE) in 30 fractions was delivered, and an additional boost of 4-10 GyE was given when residual tumors were suspected. The median follow-up time was 24 months (range=7-66 months).

RESULTS:

No cardio-pulmonary toxicities of grade 3 or higher were observed. Recurrences were observed in 16 patients, and the 2-year rates of disease-specific survival and locoregional control were 77% and 66%, respectively.

CONCLUSION:

Irrespective of the small sample size and short follow-up time of the study, proton beam therapy combined with chemo therapy seems to be feasible for esophageal cancer.

KEYWORDS:

Proton beam therapy; concurrent chemoradiotherapy; esophageal cancer; late toxicity; survival

PMID:
25750339
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center